Abstract

Preliminary results of new therapies in the areas of cytotoxic agents and immunotherapy for advanced indolent lymphomas have been encouraging. Long-term follow-up on high-dose therapy suggests a potential role for this modality in this group of lymphomas. In aggressive lymphomas, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) continues to hold ground as first-line therapy when compared against other regimens. Several studies reinforce past findings that patients with chemosensitive relapse are better candidates for high-dose therapy. In relapsed or refractory disease, selected compounds appear to have activity as single agents and others have shown activity in combination therapy. Despite high treatment-related mortality rates, allogeneic transplantation in relapsed aggressive lymphoma warrants further investigation. Last, as patients are surviving longer, complications of therapy are having to be addressed.

Original languageEnglish (US)
Pages (from-to)412-418
Number of pages7
JournalCurrent Opinion in Oncology
Volume12
Issue number5
DOIs
StatePublished - Dec 1 2000

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Therapeutics
Homologous Transplantation
Cytotoxins
Vincristine
Prednisone
Immunotherapy
Doxorubicin
Cyclophosphamide
Recurrence
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment of non-Hodgkin lymphoma. / Hauke, Ralph J.; Armitage, James Olen.

In: Current Opinion in Oncology, Vol. 12, No. 5, 01.12.2000, p. 412-418.

Research output: Contribution to journalReview article

Hauke, Ralph J. ; Armitage, James Olen. / Treatment of non-Hodgkin lymphoma. In: Current Opinion in Oncology. 2000 ; Vol. 12, No. 5. pp. 412-418.
@article{28798c106eec4f8a894f73ab0aa122c1,
title = "Treatment of non-Hodgkin lymphoma",
abstract = "Preliminary results of new therapies in the areas of cytotoxic agents and immunotherapy for advanced indolent lymphomas have been encouraging. Long-term follow-up on high-dose therapy suggests a potential role for this modality in this group of lymphomas. In aggressive lymphomas, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) continues to hold ground as first-line therapy when compared against other regimens. Several studies reinforce past findings that patients with chemosensitive relapse are better candidates for high-dose therapy. In relapsed or refractory disease, selected compounds appear to have activity as single agents and others have shown activity in combination therapy. Despite high treatment-related mortality rates, allogeneic transplantation in relapsed aggressive lymphoma warrants further investigation. Last, as patients are surviving longer, complications of therapy are having to be addressed.",
author = "Hauke, {Ralph J.} and Armitage, {James Olen}",
year = "2000",
month = "12",
day = "1",
doi = "10.1097/00001622-200009000-00005",
language = "English (US)",
volume = "12",
pages = "412--418",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Treatment of non-Hodgkin lymphoma

AU - Hauke, Ralph J.

AU - Armitage, James Olen

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Preliminary results of new therapies in the areas of cytotoxic agents and immunotherapy for advanced indolent lymphomas have been encouraging. Long-term follow-up on high-dose therapy suggests a potential role for this modality in this group of lymphomas. In aggressive lymphomas, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) continues to hold ground as first-line therapy when compared against other regimens. Several studies reinforce past findings that patients with chemosensitive relapse are better candidates for high-dose therapy. In relapsed or refractory disease, selected compounds appear to have activity as single agents and others have shown activity in combination therapy. Despite high treatment-related mortality rates, allogeneic transplantation in relapsed aggressive lymphoma warrants further investigation. Last, as patients are surviving longer, complications of therapy are having to be addressed.

AB - Preliminary results of new therapies in the areas of cytotoxic agents and immunotherapy for advanced indolent lymphomas have been encouraging. Long-term follow-up on high-dose therapy suggests a potential role for this modality in this group of lymphomas. In aggressive lymphomas, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) continues to hold ground as first-line therapy when compared against other regimens. Several studies reinforce past findings that patients with chemosensitive relapse are better candidates for high-dose therapy. In relapsed or refractory disease, selected compounds appear to have activity as single agents and others have shown activity in combination therapy. Despite high treatment-related mortality rates, allogeneic transplantation in relapsed aggressive lymphoma warrants further investigation. Last, as patients are surviving longer, complications of therapy are having to be addressed.

UR - http://www.scopus.com/inward/record.url?scp=0034458260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034458260&partnerID=8YFLogxK

U2 - 10.1097/00001622-200009000-00005

DO - 10.1097/00001622-200009000-00005

M3 - Review article

C2 - 10975547

AN - SCOPUS:0034458260

VL - 12

SP - 412

EP - 418

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -